Tag: Asenapine

With a bioavailability of less than 2% if swallowed, the atypical antipsychotic asenapine is distinguished by its mandatory sublingual or transdermal administration. Understanding how is asenapine different from other antipsychotics reveals its unique place in treating schizophrenia and bipolar disorder.

Schizophrenia affects approximately 1 in 300 people worldwide, making effective treatment vital. One such treatment, asenapine, is an atypical antipsychotic that helps to manage symptoms of schizophrenia and bipolar disorder by uniquely targeting and rebalancing key neurotransmitters in the brain.